Spruce Biosciences
SPRB
28 hedge funds and large institutions have $20M invested in Spruce Biosciences in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 8 closing their positions.
0.77% more ownership
Funds ownership: 76.61% → 77.38% (+0.77%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
19% less capital invested
Capital invested by funds: $24.7M → $20M (-$4.77M)
20% less funds holding
Funds holding: 35 → 28 (-7)
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
+$56.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$19.9K |
| 3 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$4.69K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.02K |
| 5 |
Millennium Management
New York
|
+$2.76K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
-$32K |
| 2 |
B
Bailard
Foster City,
California
|
-$29K |
| 3 |
Goldman Sachs
New York
|
-$27K |
| 4 |
Morgan Stanley
New York
|
-$22.1K |
| 5 |
SG
StoneX Group
New York
|
-$13.8K |
SPRB Hedge Fund Activity: Q4 2022 in Review
28 of the 6,239 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q4 2022, worth a combined $20M — down 19% from $24.7M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SPRB and 2 opened new positions — a net loss of 6 holders — while 7 trimmed existing stakes and 7 added.
The largest buyer was Privium Fund Management (UK), opening a new position worth an estimated $56.3K. The largest seller was Ergoteles, exiting entirely with an estimated $32K sold.
- 28 institutional investors held Spruce Biosciences (SPRB) as of Q4 2022, down from 35 in Q3 2022.
- Funds reported $20M of Spruce Biosciences stock for Q4 2022, down 19% quarter-over-quarter.
- 2 funds opened new Spruce Biosciences positions in Q4 2022 and 8 closed out, a net change of -6 holders.
- The largest Spruce Biosciences buyer in Q4 2022 was Privium Fund Management (UK), an estimated $56.3K added.
- The largest Spruce Biosciences seller in Q4 2022 was Ergoteles, an estimated $32K sold.
Based on aggregated 13F filings for Q4 2022.